Special Issue "Pneumococcal Vaccine in the 21st Century"

Quicklinks

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 August 2013)

Special Issue Editor

Guest Editor
Dr. Stanley S. Tai

Department of Microbiology, College of Medicine, Howard University, 520 “W” Street, NW, Washington, DC 20059, USA
Phone: +1 202 806 4677
Fax: +1 202 667 9589
Interests: pneumococcal vaccine; respiratory bacterial pathogens; bacterial pathogenesis

Special Issue Information

Dear Colleagues,

Streptococcus pneumoniae infection is one of the leading infectious diseases with great morbidity and mortality worldwide, especially in the elderly and young children. The United States Food and Drug Administration has licensed a 7-valent pneumococcal conjugate vaccine Prevnar 7® in 2000 for use in young children. It reduces the incidence rate of invasive pneumococcal disease and acute otitis media significantly in immunized children and, via herd immunity, in adults. However, its use is limited by the variations in prevalent serotypes among different geographic areas and the increase of non-vaccine type pneumococcal infection after use. To broaden the protection, Prevnar 13® was licensed in 2010. This special issue will cover, but not limit to, the following areas: 1) the impact of Prevnar 13® on the incidence rate of pneumococcal disease in vaccinated and non-vaccinated populations, and the serotype distribution and antibiotic susceptibility of S. pneumoniae isolated from patients and healthy populations, 2) the development of new polysaccharide-based vaccines for the countries that cannot be effectively protected by Prevnar 13®, and 3) the advances in polysaccharide-independent pneumococcal vaccines, such as pneumococcal protein antigens, whole cell vaccines, and recombinant bacteria carrying pneumococcal antigens. The book will be a mix of original research, review articles and commentaries that are focused on the effectiveness of current vaccine and the development of future pneumococcal vaccines.

Dr. Stanley S. Tai
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

  • streptococcus pneumoniae
  • pneumococcal vaccine
  • pneumococcal conjugate vaccine
  • pneumococcoal invasive disease
  • pneumococcal protein antigen
  • post-immunization
  • prevnar 7
  • prevnar 13
  • streptococcus pneumoniae serotype distribution
  • streptococcus pneumoniae antibiotic susceptibility

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Review

Open AccessReview Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention
Vaccines 2014, 2(1), 112-128; doi:10.3390/vaccines2010112
Received: 2 December 2013 / Revised: 18 January 2014 / Accepted: 6 February 2014 / Published: 14 February 2014
Cited by 4 | PDF Full-text (336 KB) | HTML Full-text | XML Full-text
Abstract
Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, [...] Read more.
Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines. Full article
(This article belongs to the Special Issue Pneumococcal Vaccine in the 21st Century)
Open AccessReview Development of Streptococcus pneumoniae Vaccines Using Live Vectors
Vaccines 2014, 2(1), 49-88; doi:10.3390/vaccines2010049
Received: 11 October 2013 / Revised: 9 November 2013 / Accepted: 27 December 2013 / Published: 7 January 2014
Cited by 4 | PDF Full-text (766 KB) | HTML Full-text | XML Full-text
Abstract
Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as serotype replacement, [...] Read more.
Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as serotype replacement, limited coverage and high costs. A recombinant live vector vaccine delivering protective antigens is a promising way to achieve this goal. In this review, we discuss the researches using live recombinant vaccines, mainly live attenuated Salmonella and lactic acid bacteria, to deliver pneumococcal antigens. We also discuss both the limitations and the future of these vaccines. Full article
(This article belongs to the Special Issue Pneumococcal Vaccine in the 21st Century)

Journal Contact

MDPI AG
Vaccines Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
vaccines@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Vaccines
Back to Top